Characteristics of hormone-treated prostate carcinoma: stressing the need for clinician-pathologist communication.
OBJECTIVE
Patients scheduled for prostatectomy often receive androgen deprivation therapy to make malignant tumors more amenable to resection and improve the postoperative course. These hormonal therapies may significantly alter the histomorphology of carcinoma of the prostate detected on subsequent needle biopsies.


METHODS
Needle specimens were obtained from resected prostates harboring biopsy-proven carcinoma previously treated with leuprolide. The tissue was examined by light microscopy to note architectural and cytologic characteristics.


RESULTS
A high proportion of treated carcinomas had an atrophic, infiltrative appearance. Nuclear and nucleolar enlargement were consistently observed. Macronucleoli, blue-tinged mucin, and intraluminal pink amorphous material was frequently identified.


CONCLUSIONS
The markedly atrophic nature of the cells and glands may result in either overgrading of prostate carcinoma or failure to recognize the more subtle patterns of this malignant neoplasm. It is imperative that clinicians convey a history of hormone treatment to pathologists when core biopsies of the prostate are submitted for histologic evaluation.
Trummel
D E
DE
Department of Pathology, Wilford Hall Medical Center, Lackland Air Force Base, TX 78236-5300, USA.
McCabe
K M
KM
Cina
S J
SJ
D000230:Adenocarcinoma / Q000473:pathology* / Q000628:therapy*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001707:Biopsy, Needle; D003142:Communication; D006801:Humans; D007400:Interprofessional Relations; D016729:Leuprolide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008887:Military Medicine; D008889:Military Personnel; D010338:Pathology, Clinical; D010819:Physician's Role; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide